INTENSITY THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- INTENSITY THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $1.60M, a 40.10% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $150.00K, a 54.27% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $2.68M.
- INTENSITY THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $328.00K.
- INTENSITY THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2025 was $3.59M, a 163.63% increase from fiscal 2024.
- INTENSITY THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2024 was $1.36M, a 92.85% decline from fiscal 2023.
- INTENSITY THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2023 was $19.02M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $1.60M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $150.00K 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $3.59M 10-K · filed 2026-03-27 | |
| 2025-06-30 | $2.68M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $328.00K 10-Q · filed 2026-05-07 | |
| 2024-12-31 | $1.36M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $150.00K 10-Q · filed 2024-11-13 | |
| 2023-12-31 | $2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $19.02M 10-K · filed 2025-03-13 |
| 2023-09-30 | $2.55M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $16.47M 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |